MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Fenretinide

CAS No. : 65646-68-6

MCE 国际站：Fenretinide

产品活性：Fenretinide (4-HPR) 是一种合成的类维生素A衍生物，能够结合视黄酸受体 (RAR) 诱导细胞死亡。

研究领域：Metabolic Enzyme/Protease  |  Vitamin D Related/Nuclear Receptor  |  Autophagy

作用靶点：RAR/RXR  |  Autophagy

In Vitro: Fenretinide (4-HPR) exerts not just acute but also long term antitumor activity in selected T-ALL cell lines. Fenretinide inhibits DES activity in CCRF-CEM leukemia cells in a dose and time dependent manner, leading to a concomitant increase of the endogenous cellular dhCer content. Fenretinide (3 μM)-induced dhCer accumulation in both CCRF-CEM and Jurkat cells. Ceramide inhibition with fenretinide protects insulin signaling. Fenretinide prevents lipid-induced reductions in insulin-stimulated glucose uptake. Fenretinide inhibits OVCAR-5 cell proliferation and viability at concentrations higher than 1 microM, with 70-90% growth inhibition at 10 microM. Fenretinide (1 microM) significantly inhibits OVCAR-5 invasion after 3 days preincubation. Endothelial cells treated with 1 microM 4-HPR fails to form tubes, but forms small cellular aggregates.

In Vivo: Fenretinide (4-HPR) (10 mg/kg, i.p.) selectively inhibits ceramide accumulation HFD-fed male C57Bl/6 mice. Fenretinide treatment improves glucose tolerance and insulin sensitivity as determined by both glucose and insulin tolerance tests. Addition of 25 mg/kg ketoconazole to Fenretinide in NOD/SCID mice increased 4-HPR plasma levels.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Anti-diabetic Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Blood Cancer Compound Library  |  Transcription Factor-Targeted Library  |  Rare Diseases Drug Library  |  Protein-protein Interaction Inhibitor Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Anti-Prostate Cancer Compound Library  |  Nuclear Receptor Compound Library  |  Off-patent Drug Library  |  Mitochondrial Toxicity Compound Library  |  Tazarotene-d₈  |  Retinoic acid  |  LG101506  |  CD2314  |  BMS453  |  ATRA-biotin  |  BPA-B9  |  AGN 193109  |  Magnolol  |  AGN 194078  |  Tazarotene  |  (-)-Talarozole  |  Bigelovin  |  Ch55  |  AGN-195183  |  BMS-195614  |  LG-100064  |  AC-261066  |  Liarozole  |  BMS641  |  Tamibarotene  |  PA452  |  Tarenflurbil  |  9-cis-Retinoic acid-d₅  |  Fluorobexarotene  |  Retinoic acid-d₆  |  Adapalene  |  Oxybenzone  |  CD2665

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。